Clinical Trial

Effect of Preoperative Intrathecal Dexamethasone Versus Dexmedetomidine on Paralytic Ileus After Major Abdominal Surgery

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Postoperative Ileus (POI) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (GI) tract following abdominal or non-abdominal surgery. Dexamethasone \& Dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries. Previous study has shown that a single dose of DM before induction of anesthesia may be beneficial to reduce ileus for IBD by alleviating the postoperative systemic inflammatory response. Perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability. The aim of this study is to compare the effect of preoperative intrathecal dexamethasone versus dexmedetomidine on paralytic ileus after major abdominal surgery.
Trial Details
NCT Number NCT06752317
Lead Sponsor Assiut University
Conditions Paralytic Ileus
Enrollment 60 participants
Start Date 2025-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-30